GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forward Pharma A/S (OTCPK:FWPAY) » Definitions » Debt-to-EBITDA

Forward Pharma A/S (Forward Pharma A/S) Debt-to-EBITDA : 4.84 (As of Jun. 2022)


View and export this data going back to 2014. Start your Free Trial

What is Forward Pharma A/S Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Forward Pharma A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $2.95 Mil. Forward Pharma A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $0.00 Mil. Forward Pharma A/S's annualized EBITDA for the quarter that ended in Jun. 2022 was $0.61 Mil. Forward Pharma A/S's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was 4.84.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Forward Pharma A/S's Debt-to-EBITDA or its related term are showing as below:

FWPAY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.16   Med: -0.13   Max: -0.09
Current: -1.16

During the past 11 years, the highest Debt-to-EBITDA Ratio of Forward Pharma A/S was -0.09. The lowest was -1.16. And the median was -0.13.

FWPAY's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.36 vs FWPAY: -1.16

Forward Pharma A/S Debt-to-EBITDA Historical Data

The historical data trend for Forward Pharma A/S's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forward Pharma A/S Debt-to-EBITDA Chart

Forward Pharma A/S Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Forward Pharma A/S Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 4.84

Competitive Comparison of Forward Pharma A/S's Debt-to-EBITDA

For the Biotechnology subindustry, Forward Pharma A/S's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forward Pharma A/S's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forward Pharma A/S's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Forward Pharma A/S's Debt-to-EBITDA falls into.



Forward Pharma A/S Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Forward Pharma A/S's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -3.874
=0.00

Forward Pharma A/S's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.945 + 0) / 0.608
=4.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2022) EBITDA data.


Forward Pharma A/S  (OTCPK:FWPAY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Forward Pharma A/S Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Forward Pharma A/S's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Forward Pharma A/S (Forward Pharma A/S) Business Description

Traded in Other Exchanges
N/A
Address
Ostergade 24A, 1st Floor, Copenhagen, DNK, 1100
Forward Pharma A/S is a biopharmaceutical company that engages in the research and production of medicinal treatments for multiple sclerosis and psoriasis.

Forward Pharma A/S (Forward Pharma A/S) Headlines